
|Articles|October 1, 2003
Iris-claw phakic IOL found to be safe for treating hyperopia
Author(s)Cheryl Guttman
Stanford, CA-The phase III trial of the iris-claw phakic IOL (Artisan, Ophtec) for the treatment of hyperopia is now 2 years post- launch, and the short- and long-term results from the interim analyses are very encouraging, said Edward E. Manche, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dr. Mali’s top 5 predictions in ophthalmology for 2026
2
FDA clears Novaliq’s Investigational New Drug application for NOV05
3
Eye exams could enable earlier detection of systemic disease
4
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
5



























